Boston Scientific 8-K

Leadership changeExecutive pay

David S. Wichmann to succeed Ludwig as lead independent director; 2027 executive incentives tie payouts to sales, adjusted EPS and shareholder returns

Filed 2026-11-17 16:08 ET

Summary

Lead independent director appointment and 2027 executive incentive plans. David S. Wichmann will become Lead Independent Director on 1/1/2027, succeeding Edward J. Ludwig, who will remain on the Board; Wichmann has been a director since 2021 and chairs the Audit Committee. The Board also approved 2027 annual cash bonuses and three-year performance-share programs that tie executive compensation to company sales, adjusted earnings per share and shareholder returns.

Key Figures

  • 2027 annual bonus pool: participants’ total target bonuses multiplied by a company performance distribution percentage of 0%–150%, plus a dynamic pool of up to 10% of total target bonuses. Company performance is measured against global sales and adjusted earnings per share goals; the Board may reduce the distribution based on quality objectives and quality-system performance. Individual modifiers range from 0%–150%, with maximum individual payouts of 225% of target.
  • 2027 relative total shareholder return performance-share program: performance over 1/1/2027–12/31/2029 is measured against companies in the S&P 500 Healthcare Index; awards range from 0%–200% of target based on the Company’s total shareholder return rank.
  • 2027 organic net sales growth performance-share program: performance over 1/1/2027–12/31/2029 is measured against the Company’s financial plan for organic net sales growth. The plan defines organic net sales as excluding foreign-currency effects and certain acquisitions and divestitures without a full comparable period; awards range from 0%–200% of target.

Was this summary useful?

The summary is written by an AI model reading the filing.

Model 005 · prompt v192 · 2026-11-17 23:35:49Z

Feedback